Search

Session information—March 25, 2025

Topic'Infections caused by multidrug-resistant (MDR) pathogens in hematological patients.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more

Press release: Theme of the Year and Patient Advocacy - 18th Congress of EHA - European Hematology Association

This year for the first time, the EHA congress program is complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.

Read more

Burnout survey

The burnout survey closed on October 25, 2024. Burnout in hematologyBurnout is, in broad terms, a state of physical, mental, and emotional exhaustion.

Read more

HemaSphere, the Official Journal of the European Hematology Association, Receives Its First Impact Factor

The Hague, June 2022 - HemaSphere, the official peer-reviewed journal of the European Hematology Association (EHA), has received its first Journal Impact Factor™. The preliminary 2021 Journal Impact Factor for HemaSphere is 8.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Regulation on Health Technology Assessment

The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.

Read more

Health data

Health data plays a substantial role in the European Union’s strategic, legislative, and funding initiatives in the health domain.

Read more